Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 3,574 matching trials from the live ClinicalTrials.gov search.
Conditions
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Interventions
zanubrutinib, bendamustine, rituximab
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
60 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
12
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts + 9 more
Active, not recruiting No phase listed Observational

Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma

NCT07777120
Conditions
Marginal Zone Lymphoma
Interventions
lisocabtagene maraleucel
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2048
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
168
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 119 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
Busulfan, Cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Mantle Cell Lymphoma in Relapse, Diffuse Large B Cell Lymphoma in Relapse, Other B Cell Lymphoma in Relapse, Plasma Cell Leukemia
Interventions
SNS01-T
Biological
Lead sponsor
Senesco Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Little Rock, Arkansas • Rochester, Minnesota • Hackensack, New Jersey + 2 more
Conditions
Multiple Myeloma, Non-Hodgkins Lymphoma
Interventions
Plerixafor
Drug
Lead sponsor
Shi, Patricia, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Conditions
Leukemia, Lymphoma
Interventions
Insulin Glargine, Insulin Aspart
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Mesna, CD19-CD22 CAR T cell infusion
Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Lymphoma
Interventions
CAT-8015
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Beverly Hills, California • Bethesda, Maryland
Conditions
Relapsed or Refractory T Cell Lymphoma
Interventions
ONO-4685
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 17 more
Conditions
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions
Pirtobrutinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
17
States / cities
Miami, Florida • Sarasota, Florida • Atlanta, Georgia + 14 more
Conditions
Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
AFM11
Drug
Lead sponsor
Affimed GmbH
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive, Minimal Residual Disease, Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Tisagenlecleucel
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Renal Cell Carcinoma, Breast Cancer, Colon Cancer, Lung Cancer, Non-Hodgkin Lymphoma
Interventions
DMS 612
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Bethesda, Maryland • Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
filgrastim, graft-versus-tumor induction therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
B-cell Non-Hodgkin Lymphoma
Interventions
Mosunetuzumab, Polatuzumab Vedotin, Rituxumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 12 more
Conditions
Lymphoma, Disorder Related to Bone Marrow Transplantation
Interventions
Fludarabine, Melphalan, Allogeneic Transplant, Thymoglobulin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell Neoplasm
Interventions
Vincristine, Prednisone, Doxorubicin, Etoposide, Pomalidomide, Cyclophosphamide, Rituximab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
Interventions
Venetoclax, AMG 176
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Iowa City, Iowa + 6 more
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, cisplatin, cytarabine, etoposide, ifosfamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 LL2 IgG, yttrium Y 90 epratuzumab
Biological · Drug · Procedure + 1 more
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Belleville, New Jersey
Conditions
Advanced Cancer, Colorectal Cancer, Mantle Cell Lymphoma
Interventions
Ramucirumab, Merestinib, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Birmingham, Alabama • Houston, Texas
Conditions
Non-Hodgkin Lymphoma
Interventions
Chemotherapy and Radioimmunotherapy
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
T Cell Lymphoma
Interventions
Fostamatinib Disodium
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Francisco, California • Stanford, California • Atlanta, Georgia + 5 more
Conditions
Peripheral T-Cell Lymphoma
Interventions
KW-0761
Biological
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 2 more